TNF and inflammatory bowel disease: Through a transcriptional analysis of mucosal samples, Trilleaud and colleagues showed that ChemR23, a GPCR targeted by resolvin E1, was highly expressed in the inflamed gut of IBD patients unresponsive to biologics (i.e. TNFα blockers or vedolizumab) and associated with significant mucosal neutrophil accumulation.